Genentech announced that the FDA accepted its Biologics License Application (BLA) for its Port Delivery System (PDS) with ranibizumab.
PDS, a permanent, refillable eye implant standing at the approximate size of a grain of rice offers continuous delivery of a customized formulation of ranibizumab over a period of months with the intention of reducing the treatment burden associated with frequent eye injections.
Get the full story at our sister site, Drug Delivery Business News.